newsfilter
← Latest News
PR Newswire·

Kindred Biosciences Unveils Positive Results from Pilot Study of its Interleukin-4R Monoclonal Antibody Being Developed for the Treatment of Atopic Dermatitis in Dogs

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today...